Nüks Etmiş/Dirençli Hematolenfatik Kanserlerin Tedavisinde UTAA09 Enjeksiyonu

Sade dilde özet

Bu çalışma, nüks etmiş veya tedaviye dirençli, CD19-pozitif B hücreli kan ve lenf sistemi kanserleri olan hastalarda UTAA09 adlı bir hücre tedavisini, Fludarabine ve Cyclophosphamide ile birlikte incelemektedir. Çalışmaya, 3-70 yaş arası, uygun organ fonksiyonlarına sahip hastalar alınmaktadır. Çalışma Erken Faz 1 aşamasında yürütülmekte ve halen katılımcı almaktadır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

Erken Faz 1 (Early Phase 1)

Durum

Katılımcı alıyor

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Müdahale

UTAA09 cells for infusion, Fludarabine, Cyclophosphamide

Başlangıç

01.10.2023

Tahmini bitiş

01.04.2028

Ülkeler

China

İlgili genler

Merkezler

• Hefei, China

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

1. Patients aged between 3\~70 (including cut-off values), regardless of gender and race;
2. Expected survival time\>12 weeks;
3. ECOG score 0-2;
4. CD19-positive relapsed/refractory B-cell hematolymphatic malignancies;
5. Liver and kidney function, cardiopulmonary function meet the following requirements:

   1. Creatinine ≤ 1.5 ULN;
   2. Left ventricular ejection fraction ≥ 45%;
   3. blood oxygen saturation\>91%;
   4. Total bilirubin ≤ 1.5 × ULN； ALT and AST ≤ 2.5 × ULN;
6. Be able to understand the trial and have signed the informed consent.

Exclusion Criteria:

1. Those with graft-versus-host disease (GVHD) or requiring long-term systemic immunosuppressants;
2. Malignant tumors other than CD19-positive hematologic malignancies within 5 years prior to screening, except adequately treated cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, local prostate cancer after radical resection, and breast ductal carcinoma in situ after radical resection;
3. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer outside the normal reference range; Those who are positive for hepatitis C virus (HCV) antibodies and positive for hepatitis C virus (HCV) RNA in peripheral blood; Human immunodeficiency virus (HIV) antibody positive person; Positive for cytomegalovirus (CMV) DNA testing; those who test positive for syphilis;
4. Serious heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥ III), and serious arrhythmia;
5. Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
6. Within 7 days before screening, there is active infection or uncontrollable infection requiring systemic treatment (except for mild genitourinary system infection and upper respiratory tract infection);
7. Pregnant or lactating women, female subjects who planned to conceive within 1 year of cell infusion or male subjects whose partner planned pregnancy within 1 year of their cell infusion;
8. Screening participants (except for inhalation or local use) who were receiving systemic steroid treatment within 7 days before screening or who were judged by the investigator to require long-term systemic steroid therapy during treatment;
9. Participated in other clinical studies within 3 month before screening;
10. There was evidence of central nervous system involvement at participant screening;
11. Conditions that the investigators considered unsuitable for enrollment.